Aptose Biosciences (APTO) to Delist from Nasdaq as of April 2, 2025 Apr 1, 2025 08:30AM
Aptose Biosciences (APTO) PT Raised to $6 at H.C. Wainwright Mar 31, 2025 06:41AM
Aptose Biosciences (APTO) Regains Nasdaq Compliance Mar 17, 2025 07:31AM
Aptose Biosciences (APTO) Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Feb 20, 2025 07:33AM
Aptose Biosciences (APTO) Announces 1:30 Reverse Share Split Feb 18, 2025 04:30PM


Feb 13, 2025 04:30PM Aptose Biosciences (APTO) Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
Dec 19, 2024 04:05PM Aptose Biosciences (APTO) Announces Positive Decision by Nasdaq Hearings Panel
Dec 12, 2024 10:16AM Aptose Biosciences (APTO) Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality
Dec 4, 2024 06:50AM H.C. Wainwright Reiterates Buy Rating on Aptose Biosciences (APTO)
Nov 22, 2024 08:01AM Aptose Biosciences (APTO) Announces Pricing of $8 Million Public Offering
Aug 30, 2024 04:31PM Aptose Biosciences (APTO) Receives $10M Through a Facility Agreement with Hanmi
Aug 8, 2024 06:30PM Aptose Biosciences (APTO) Misses Q2 EPS by 43c
Jul 19, 2024 05:01PM Aptose Biosciences (APTO) Receives Nasdaq Non-compliance Notice
Jun 11, 2024 06:18AM Aptose Biosciences (APTO) PT Lowered to $7 at H.C. Wainwright